Assembly Biosciences, Inc. SEC filings ASMB
Assembly Biosciences, Inc. has 901 filings in SEC EDGAR's recent list, going back to Feb 7, 2008. Its latest annual report, Form ARS, was filed on Apr 22, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 13, 2026 (acquisition or sale of assets). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Apr 22, 2026 | — |
| DEF 14A | Proxy statement | Apr 22, 2026 | Jun 4, 2026 |
| DEFA14A | Additional proxy material | Apr 23, 2025 | — |
| DEF 14A | Proxy statement | Apr 23, 2025 | Jun 5, 2025 |
| DEFA14A | Additional proxy material | Apr 17, 2024 | — |
| DEF 14A | Proxy statement | Apr 17, 2024 | May 29, 2024 |
| DEFA14A | Additional proxy material | Dec 21, 2023 | — |
| DEF 14A | Proxy statement | Dec 21, 2023 | Jan 31, 2024 |
| PRE 14A | Preliminary proxy statement | Dec 11, 2023 | Jan 31, 2024 |
| DEFA14A | Additional proxy material | Apr 12, 2023 | — |
| DEF 14A | Proxy statement | Apr 12, 2023 | May 25, 2023 |
| PRE 14A | Preliminary proxy statement | Mar 31, 2023 | May 25, 2023 |
| DEFA14A | Additional proxy material | Apr 12, 2022 | — |
| DEF 14A | Proxy statement | Apr 12, 2022 | May 25, 2022 |
| PRE 14A | Preliminary proxy statement | Apr 1, 2022 | May 25, 2022 |
| DEFA14A | Additional proxy material | Apr 7, 2021 | — |
| DEF 14A | Proxy statement | Apr 7, 2021 | May 20, 2021 |
| DEFA14A | Additional proxy material | May 19, 2020 | — |
| DEFA14A | Additional proxy material | Apr 27, 2020 | — |
| DEF 14A | Proxy statement | Apr 27, 2020 | Jun 11, 2020 |
| PRE 14A | Preliminary proxy statement | Apr 16, 2020 | Jun 11, 2020 |
| DEFA14A | Additional proxy material | Apr 4, 2019 | — |
| DEF 14A | Proxy statement | Apr 4, 2019 | May 17, 2019 |
| DEFA14A | Additional proxy material | Apr 19, 2018 | — |
| DEF 14A | Proxy statement | Apr 19, 2018 | May 30, 2018 |
| PRE 14A | Preliminary proxy statement | Apr 6, 2018 | May 30, 2018 |
| DEFA14A | Additional proxy material | Apr 21, 2017 | — |
| DEF 14A | Proxy statement | Apr 21, 2017 | Jun 1, 2017 |
| DEFA14A | Additional proxy material | Apr 22, 2016 | — |
| DEFA14A | Additional proxy material | Apr 22, 2016 | — |
| DEF 14A | Proxy statement | Apr 22, 2016 | Jun 2, 2016 |
| DEFA14A | Additional proxy material | May 14, 2015 | — |
| DEFA14A | Additional proxy material | Apr 13, 2015 | — |
| DEF 14A | Proxy statement | Apr 13, 2015 | May 28, 2015 |
| DEFA14A | Additional proxy material | Jun 25, 2014 | — |
| DEFA14A | Additional proxy material | Jun 9, 2014 | — |
| DEF 14A | Proxy statement | Jun 9, 2014 | Jul 10, 2014 |
| PRE 14A | Preliminary proxy statement | May 19, 2014 | May 19, 2014 |
| DEFA14A | Additional proxy material | May 19, 2014 | — |
| DEFA14A | Additional proxy material | Apr 19, 2013 | — |
| DEF 14A | Proxy statement | Apr 19, 2013 | Jun 4, 2013 |
| DEF 14A | Proxy statement | Apr 9, 2012 | May 8, 2012 |
| DEF 14A | Proxy statement | Apr 27, 2011 | May 19, 2011 |
Showing 43 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ASMB (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- South San Francisco, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1426800
- Former names
- VENTRUS BIOSCIENCES INC (until Jul 11, 2014)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.